- Home
- HBM vs MRUS Comparison
HBM vs MRUS Comparison
Compare HBM & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBM
- MRUS
- Stock Information
- Founded
- HBM 1927
- MRUS 2003
- Country
- HBM Canada
- MRUS Netherlands
- Employees
- HBM N/A
- MRUS N/A
- Industry
- HBM Metal Mining
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- HBM Basic Materials
- MRUS Health Care
- Exchange
- HBM Nasdaq
- MRUS Nasdaq
- Market Cap
- HBM 5.4B
- MRUS 5.1B
- IPO Year
- HBM N/A
- MRUS 2016
- Fundamental
- Price
- HBM $16.23
- MRUS $94.81
- Analyst Decision
- HBM Strong Buy
- MRUS Buy
- Analyst Count
- HBM 1
- MRUS 18
- Target Price
- HBM $19.50
- MRUS $93.72
- AVG Volume (30 Days)
- HBM 7.9M
- MRUS 2.6M
- Earning Date
- HBM 11-12-2025
- MRUS 10-31-2025
- Dividend Yield
- HBM 0.09%
- MRUS N/A
- EPS Growth
- HBM 216.33
- MRUS N/A
- EPS
- HBM 0.72
- MRUS N/A
- Revenue
- HBM $2,202,000,000.00
- MRUS $56,228,000.00
- Revenue This Year
- HBM $13.99
- MRUS $51.77
- Revenue Next Year
- HBM N/A
- MRUS N/A
- P/E Ratio
- HBM $22.43
- MRUS N/A
- Revenue Growth
- HBM 8.31
- MRUS 59.77
- 52 Week Low
- HBM $5.95
- MRUS $33.19
- 52 Week High
- HBM $17.73
- MRUS $95.30
- Technical
- Relative Strength Index (RSI)
- HBM 57.27
- MRUS 79.21
- Support Level
- HBM $14.94
- MRUS $94.59
- Resistance Level
- HBM $15.91
- MRUS $95.06
- Average True Range (ATR)
- HBM 0.69
- MRUS 0.36
- MACD
- HBM -0.22
- MRUS -1.00
- Stochastic Oscillator
- HBM 48.71
- MRUS 47.87
About HBM Hudbay Minerals Inc. (Canada)
Hudbay Minerals Inc is a Canadian mining company with its operations, property developments, and exploration activities across the United States. The mines that Hudbay operates are located in Manitoba, Canada, Arizona, United States; and Peru. The company is principally focused on the discovery, production, and marketing of base and precious metals. Hudbay produces copper concentrate, which contains copper, gold, and silver, as well as zinc metal. More than half the company's revenue is attributable to the copper business. The company sells copper concentrates to smelters across Asia, America, and Europe, and sells Zinc metal, another source of revenue, to industrial customers across North America.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.